Skip to main content
    S

    Soleno Therapeutics Inc (SLNO)

    Official site

    BIOTECHNOLOGY

    $53.01
    +0.00 (+0.00%)

    Last updated: May 19, 2026 at 5:00 PM ET

    Soleno Therapeutics Inc (SLNO) Financials: Revenue, Profit and Cash Flow

    Updated May 7, 2026. Financial statements from company filings, amounts in US dollars.

    Soleno Therapeutics reported revenue of $190.41M for the fiscal year ended Dec 31, 2025. That year, net income was $20.89M with a net margin of 11.0%, operating cash flow was $46.80M and free cash flow was $46.73M. The quarter ended Mar 31, 2026 had revenue of $94.60M and net income of $31.38M.

    Revenue and Margins

    The operating margin was 4.9% in the fiscal year ended Dec 2025.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$190.41MN/A98.6%4.9%11.0%
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Mar 2026, net income turned positive after a loss in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$190.41M$0$0$0$0$0$0$0$0$0
    Cost of revenue$2.70M$0$0$0$0$0$0$0$0$0
    Gross profit$187.71M$0$0$0$0$0$0$0$0$0
    Research and development$40.63M$78.57M$25.19M$15.27M$21.45M$23.19M$16.27M$7.18M$3.07M$2.25M
    Operating income$9.41M-$187.67M-$41.38M-$24.40M-$31.53M-$36.29M-$23.49M-$14.30M-$12.17M-$8.32M
    Net income$20.89M-$175.85M-$38.99M-$24.07M-$30.91M-$24.64M-$30.77M-$13.34M-$15.38M-$12.07M
    EBITDAN/AN/A-$39.61M-$22.40M-$28.95M-$22.68MN/A-$11.71M-$11.83M-$6.72M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Revenue$94.60M$91.73M$66.02M$32.66M$0$0$0$0$0$3.45M$0$0
    Gross profit$93.41M$90.87M$64.88M$31.96M$0N/A$0$0$0$2.96M$0$0
    Operating income$31.28M$39.58M$22.11M-$6.53M-$45.74M-$59.12M-$80.21M-$24.87M-$23.48M-$13.91M-$10.38M-$8.62M
    Net income$31.38M$43.36M$26.01M-$4.71M-$43.77M-$55.98M-$76.62M-$21.85M-$21.40M-$11.30M-$10.86M-$8.47M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $50.59M by $19.52M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$563.83M$330.97M$180.69M$26.50M$35.55M$64.98M$38.17M$43.15M$39.02M$5.56M
    Current assets$355.81M$293.89M$171.36M$15.65M$22.42M$50.24M$21.14M$24.67M$17.99M$3.80M
    Cash and equivalents$70.11M$87.93M$169.68M$14.60M$21.30M$49.22M$20.73M$23.10M$17.10M$2.73M
    Total liabilities$113.72M$85.86M$23.18M$16.15M$17.76M$19.43M$23.23M$12.74M$12.21M$2.13M
    Short-term debt$726.00K$526.00K$273.00K$155.00K$282.00K$139.00K$305.00KN/AN/AN/A
    Long-term debt$49.86M$49.83M$0N/AN/AN/AN/AN/A$0$0
    Shareholder equity$450.12M$245.11M$157.51M$10.35M$17.79M$45.55M$14.95M$30.41M$26.82M$3.44M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total assets$608.39M$563.83M$599.89M$332.31M$318.09M$330.97M$296.71M$304.13M$168.84M$180.69M$63.55M$30.94M
    Total liabilities$112.59M$113.72M$105.09M$92.17M$85.83M$85.86M$32.01M$23.37M$25.45M$23.18M$40.33M$18.52M
    Cash and equivalents$133.03M$70.11M$246.66M$76.50M$81.33M$87.93M$48.41M$57.02M$42.85M$169.68M$52.44M$19.37M
    Shareholder equity$495.80M$450.12M$494.81M$240.14M$232.26M$245.11M$264.70M$280.76M$143.39M$157.51M$23.22M$12.43M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 99.9% of operating cash flow. Share repurchases came to 214.3% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$46.80M-$69.10M-$24.94M-$20.78M-$27.77M-$25.22M-$17.38M-$11.68M-$9.95M-$13.50M
    Capital expenditures$73.00K$218.00K$0$13.00K$22.00K$7.00K$21.00K$8.00K$575.00K$14.79K
    Free cash flow$46.73M-$69.31M-$24.94M-$20.79M-$27.79M-$25.23M-$17.40M-$11.69M-$10.53M-$13.51M
    Share repurchases$100.15M$0$0N/A$0N/AN/AN/AN/AN/A
    Investing cash flow-$201.78M-$225.68M$0-$13.00K-$22.00K-$7.00K$528.00K-$180.00K$154.00K-$38.68K
    Financing cash flow$137.16M$213.03M$180.02M$14.09M-$128.00K$53.72M$14.48M$17.83M$24.17M$10.77M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Operating cash flow$25.98M$48.70M$43.45M-$12.61M-$32.75M-$23.99M-$14.93M-$17.65M-$12.53M-$6.31M-$6.33M-$5.57M
    Capital expenditures$40.00K$58.00K$1.00K$9.00K$5.00K$8.00K$191.00K$8.00K$11.00K$0$0$0
    Free cash flow$25.94M$48.65M$43.45M-$12.62M-$32.76M-$24.00M-$15.12M-$17.66M-$12.54M-$6.31M-$6.33M-$5.57M
    Last 12 quarters

    Frequently Asked Questions About SLNO

    What is Soleno Therapeutics' annual revenue?

    Soleno Therapeutics reported revenue of $190.41M for the fiscal year ended Dec 31, 2025.

    Is Soleno Therapeutics profitable?

    Yes. Soleno Therapeutics reported net income of $20.89M for the fiscal year ended Dec 31, 2025, with a net margin of 11.0%.

    How much free cash flow does SLNO generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $46.80M minus capital expenditures of $73.00K produced free cash flow of $46.73M.

    How much debt does Soleno Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $49.86M, short-term debt of $726.00K and cash and equivalents of $70.11M.

    What is SLNO's profit margin?

    For the fiscal year ended Dec 31, 2025, Soleno Therapeutics reported gross margin of 98.6%, operating margin of 4.9% and net margin of 11.0%.